<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Schedules of Controlled Substances: Placement of Ganaxolone in Schedule V</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Schedules of Controlled Substances: Placement of Ganaxolone in Schedule V</h1>
    <p class="timestamp">Published: 2022-11-09 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>This final rule adopts, without change, an interim final rule with request for comments published in the Federal Register on June 1, 2022, placing ganaxolone (3[alpha]-hydroxy-3[beta]-methyl-5[alpha]- pregnan-20-one) and its salts in schedule V of the Controlled Substances Act. With the issuance of this final rule, the Drug Enforcement Administration maintains ganaxolone, including its salts, in schedule V of the Controlled Substances Act.</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Rule</p>
    <p><strong>Agency:</strong> Justice Department, Drug Enforcement Administration</p>
    <p><strong>Document Number:</strong> 2022-24157</p>
    <p><strong>Publication Date:</strong> 2022-11-09</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2022/11/09/2022-24157/schedules-of-controlled-substances-placement-of-ganaxolone-in-schedule-v">https://www.federalregister.gov/documents/2022/11/09/2022-24157/schedules-of-controlled-substances-placement-of-ganaxolone-in-schedule-v</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2022-24157</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
